Delving into the Latest Updates on Oxypertine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Oxypertine (JAN/USAN/INN), DP-181, WIN 18,501-2

+ [5]

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Schizophrenia

Inactive Indication-

Originator Organization

Sanofi

Active Organization

Alfresa Pharma Corp.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (11 Sep 1970),

Schizophrenia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H29N3O2

InChIKeyXCWPUUGSGHNIDZ-UHFFFAOYSA-N

CAS Registry153-87-7

A review.Nowadays, the demand for greener, more sustainable methods in organic synthesis has risen.Green synthesis emphasizes the use of renewable or recyclable resources while minimizing toxic byproducts, fostering environmentally sustainable development of essential organic frameworks.A key area of interest is the green synthesis of magnetic nanoparticles (MNPs), which have gained popularity due to their unique properties and applications in green chem.Moreover, MNPs play a pivotal role in the synthesis of indoles, an important class of compounds in medicinal chem.Indoles are core structures in many biol. active mols., including drug candidates like pindolol, oxypertine, selisistat, indomethacin, Arbidol, and sumatriptan, known for their promising pharmacol. properties.Due to their versatility and potential for functionalization, indoles are highly sought after in the development of new therapeutic agents.This review covers the eco-friendly aspects of MNPs in synthesizing indole derivatives, highlighting recent advancements in creating biol. active frameworks through green synthetic methodologies.

01 Oct 2024·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

RETRACTED ARTICLE: Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis

Review

Author: Alsaras, Ameen ; Ismail, Omar ; Albdour, Karam ; Jaber, Yazan ; Jaber, Kamel

OBJECTIVES:

The aim of this study is to indirectly compare and rank the different drugs that have been studied in randomized clinical trials (RCTs) in patients with tardive dyskinesia (TD) in terms of their efficacy in ameliorating the symptoms of TD and safety.

DESIGN:

A network meta-analysis and a systematic review were registered prospectively on PROSPERO under the ID: CRD42023407823 and were conducted in accordance with the PRISMA-NMA guidelines.

DATA SOURCES:

PubMed, Scopus, The Cochrane Central Register of Controlled Trials (CENTRAL), Web of Sciences, and Clinicaltrials.gov were searched to identify relevant records.

ELIGIBILITY CRITERIA FOR SELECTING STUDIES:

Any parallel randomized blinded controlled clinical trials that studied the use of any medications in treating TD and assessed the symptoms using a functional scale that has been previously validated.

DATA EXTRACTION:

The standardized mean difference of improvement along with the reported adverse events for each drug was extracted from each trial, and a network meta-analysis was conducted using a random-effects model.

RESULTS:

One thousand eight hundred seventeen patients in 33 RCTs were included in the analysis. Twenty-three different drugs were compared to placebo in terms of reduction in TD symptoms. Among these, valbenazine 80 mg (SMD = - 1.66, 95%CI = [- 2.55; - 0.78]), valbenazine 40 mg (- 1.00, [- 1.89; - 0.11]), and vitamin E (- 0.77, [- 1.45; - 0.1]) significantly reduced TD symptoms in comparison to placebo, while deutetrabenazine 36 mg (- 1.00, [- 2.12; 0.11]) and reserpine (- 0.54, [- 1.09; 0.02]) did not significantly reduce symptoms. Some serious adverse events were reported for valbenazine and deutetrabenazine, which included mainly psychiatric symptoms such as depression, worsening of schizophrenia, and suicidal ideation, while mild adverse events were reported for other drugs, and their incidence in the treatment arms was comparable to those in the placebo arm.

CONCLUSIONS:

Valbenazine (80 and 40 mg) and vitamin E demonstrated efficacy in treating tardive dyskinesia. However, the significant side effects of valbenazine should prompt further investigation of alternative treatment modalities.

01 Mar 2024·Journal of affective disorders

Associations between antipsychotics exposure and dementia risk: A prospective cohort study of 415,100 participants

Article

Author: Gao, Pei-Yang ; Zhang, Dan-Dan ; Tan, Lan ; Yang, Liu ; Ma, Li-Yun ; Fu, Yan ; Feng, Jian-Feng ; Yu, Jin-Tai ; Cheng, Wei ; Ou, Ya-Nan

BACKGROUND:

Antipsychotics (APs) are among the most widely prescribed medications, and have been shown to cause cognitive decline. But previous studies on their effects on dementia risk are controversial and scarce. We aimed to examine the relationships of APs exposure with the risk of dementia.

METHODS:

Data were obtained from a prospective cohort of 415,100 UK Biobank (UKB) participants. We investigated the effects of APs exposure and their various classes on dementia risk by using multivariable Cox proportional hazard models and further the dose-response effects of oral APs.

RESULTS:

After a mean follow-up of 8.64 years, 5235 (1.3 %) participants developed all-cause dementia (ACD), among whom 2313 (0.6 %) developed Alzheimer's disease (AD), and 1213 (0.3 %) developed vascular dementia (VaD). Exposure to any APs conferred increased risks of ACD (HR: 1.33, 95 % CI = 1.17-1.51, P < 0.001) and VaD (HR: 1.90, 95 % CI = 1.51-2.40, P < 0.001), but not AD (HR: 1.22, 95 % CI = 1.00-1.48, P = 0.051). Cumulative dose-response relationships of oral APs with the risks of ACD and VaD were observed (P for trend, P < 0.05).

LIMITATIONS:

Our study is observational and does not show evidence of causality. Since there are relatively few cases of dementia in the UKB, APs exposure may be higher than estimated in our study.

CONCLUSIONS:

APs exposure increased the risk of developing dementia. Dose-response relationships were found between oral APs and dementia risk. Efforts to raise awareness of doctors and patients about this potential drug-related risk are critical to reducing APs use.

100 Deals associated with Oxypertine

Login to view more data